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Validation of the Society for Vascular Surgery’s
Objective Performance Goals for critical limb
ischemia in everyday vascular surgery practice
Philip P. Goodney, MD, MS,a Andres Schanzer, MD,b Randall R. DeMartino, MD,a
Brian W. Nolan, MD, MS,a Nathanael D. Hevelone, MPH,c Michael S. Conte, MD,c
Richard J. Powell, MD,a and Jack L. Cronenwett, MD,a for the Vascular Study Group of New England,
Lebanon, NH; Worcester, Mass; and San Francisco, Calif
Background: To develop standardized metrics for expected outcomes in lower extremity revascularization for critical limb
ischemia (CLI), the Society for Vascular Surgery (SVS) has developed objective performance goals (OPGs) based on
aggregate data from randomized trials of lower extremity bypass (LEB). It remains unknown, however, if these targets
can be achieved in everyday vascular surgery practice.
Methods:We applied SVS OPG criteria to 1039 patients undergoing 1039 LEB operations for CLI with autogenous vein
(excluding patients on dialysis) within the Vascular Study Group of New England (VSGNE). Each of the individual
OPGs was calculated within the VSGNE dataset, along with its surrounding 95% confidence intervals (CIs) and
compared to published SVS OPGs using 2 comparisons and survival analysis.
Results: Across most risk strata, patients in the VSGNE and SVS OPG cohorts were similar (clinical high-risk [age >80
years and tissue loss]: 15.3% VSGNE; 16.2% SVS OPG; P .58; anatomic high risk [infrapopliteal target artery]: 57.8%
VSGNE; 60.2% SVS OPG; P  .32). However, the proportion of VSGNE patients designated as conduit high-risk (lack
of single-segment great saphenous vein) was lower (10.2% VSGNE; 26.9% SVS OPG;P < .001). The primary safety
endpoint, major adverse limb events (MALE) at 30 days, was lower in the VSGNE cohort (3.2%; 95% CI, 2.3-4.6) than
the SVS OPG cohort (6.2%; 95% CI, 4.2-8.1; P  .05). The primary efficacy OPG endpoint, freedom from any MALE
or postoperative death within the first year (MALE postoperative death [POD]), was similar between VSGNE and SVS
OPG cohorts (77%; 95% CI, 74%-80%) SVS OPG, 74% (95% CI, 71%-77%) VSGNE, P  .58). In the remaining safety
and efficacy OPGs, the VSGNE cohort met or exceeded the benchmarks established by the SVS OPG cohort.
Conclusion: Community and academic centers in everyday vascular surgery practice can meet OPGs derived from centers
of excellence in LEB. Quality improvement initiatives, as well as clinical trials, should incorporate OPGs in their outcome
measures to facilitate communication and comparison of risk-adjusted outcomes in the treatment of CLI. (J Vasc Surg
2011;54:100-8.)
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iOver 12 million patients in the United States have
peripheral arterial disease (PAD),1-4 and recent studies
estimate that nearly 1 million have the most severe form of
PAD, critical limb ischemia (CLI).5 Surgical revasculariza-
tion, while an effective treatment for CLI,6 is associated
with significant morbidity and mortality,7-10 thus making
less invasive treatment strategies desirable. Accordingly,
endovascular interventions have emerged as an alternative
to surgical arterial reconstruction.1,11 However, while
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100any have sought to compare these new and competing
ndovascular interventions to surgical bypass,12-14 meth-
dologic challenges exist in designing and executing these
tudies, and differences in patient characteristics and pro-
ibitive costs have made randomized trials and other high-
uality studies difficult to design and perform.15
Therefore, in order to establish objective benchmarks
or comparison of safety and efficacy in lower extremity
evascularization, the Society for Vascular Surgery (SVS)
ecently developed objective performance goals (OPGs) for
he treatment of CLI16,17 (Table I). These standards were
erived from the surgical results of randomized controlled
rials of several different treatments for CLI and offer a
enchmark for nonrandomized evaluation of new treat-
ents for lower extremity PAD, using the results from
ower extremity bypass (LEB) as a comparator.
It remains unknown, however, if SVS OPGs accurately
eflect everyday vascular surgery practice. The SVS OPGs
ere derived from carefully controlled studies using highly
elected patients undergoing surgery in centers of excel-
ence, where outcomes were recorded within closely mon-
tored, independently adjudicated clinical trials. Whether
he trials and results that the SVS OPGs were derived upon
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academic vascular surgery practice is unclear.
To determine if SVS OPGs accurately represent out-
comes found in the everyday practice of vascular surgery,
we studied patients undergoing LEB in the Vascular Study
Group of New England (VSGNE), a regional quality im-
provement group. We applied the SVS OPGs to patients in
the VSGNE, to discern if these targets could be reliably
obtained by surgeons practicing in a variety of settings.
METHODS
Derivation of objective performance goals. The
SVS OPGs were derived in recent work by Conte et al16 and
Geraghty et al17; the details of this derivation have been
published previously. In brief, the SVS OPGs were calcu-
lated using independently adjudicated, line-item data from
the surgical bypass arms of five multicenter randomized
trials for CLI.12,18-21 The SVS designated these OPGs as
safety and efficacy measures as outlined in Table I. CLI was
defined as ischemic rest pain or tissue loss, as well as
compromised hemodynamics (ankle pressure 50, toe
pressure 30, transcutaneous oxygen tension [TcPO2]
30). To standardize the effect of bypass conduit, only
those patients with an autogenous vein available for bypass
conduit were included. Furthermore, congruent with the
definitions listed in the OPG cohort, patients with end-
stage renal disease on dialysis were eliminated from the
analysis, given the disproportionately poor outcomes
achieved in these patients.
Construction of Vascular Study Group of New
England Cohort
Subjects. Patients undergoing LEB in hospitals par-
ticipating in the VSGNE between 2003 and 2009 (2899
Table I. Definition of objective performance goals from
the Society for Vascular Surgery Objective Performance
Goals Working Group
Safety OPGs at 30 days
MALE (amputation or major reinterventiona)
MACE (MI, stroke or death)
Above-ankle amputation
Efficacy OPGs at 1 year
Freedom from MALE or POD
Limb salvage
Survival
AFS
Freedom from RAS
Freedom from RAO
AFS, Amputation-free survival; MACE, major adverse cardiac event; MALE,
major adverse limb event; MI, myocardial infarction; OPGs, objective per-
formance goals; POD, postoperative death; RAO, reintervention or ampu-
tation; RAS, reintervention, amputation, or restenosis; VSGNE, Vascular
Study Group of New England.
aMajor reintervention: placement of new bypass graft, use of thrombectomy
or thrombolysis, or major surgical revision such as a jump or interposition
graft. NB: In the VSGNE cohort, this also includes surgical patch angio-
plasty.bypass procedures; (Appendix A, online only) were used io form the cohort for this analysis. Further details on
his registry, derived from a broad spectrum of 15 com-
unity and academic centers across New England, have
een published previously,22 and others are available at
ttp://www.vsgne.org.
To construct a cohort of patients with characteristics
imilar to those patients used to derive SVS OPGs, we
ncluded only patients who underwent open infrainguinal
ypass procedures for CLI, and eliminated all patients with
laudication (n  609; 21% of the total). Additionally, we
liminated patients who underwent bypass with prosthetic
onduit (n 564; 20% of the total), and those patients with
nd-stage renal disease (n  181; 6% of the total). We
imited this analysis to patients with occlusive disease and
liminated all patients undergoing LEB for aneurysmal
isease (n 203; 7% of the total). Inflow arteries for bypass
rocedures could be iliac, femoral, or popliteal. Bypass
arget arteries could be above-knee or below-knee, popli-
eal, tibial, or pedal. Patients with concomitant endovascu-
ar procedures (such as an iliac stent done at the time of
ypass surgery) were included in the analysis as well. Pa-
ients in whom long-term follow-up was unavailable were
lso excluded (n  93; 3% of the total). Even though the
aterality of procedures is recorded within the VSGNE,
oth before surgery and during follow-up, only the first
imb operated on per patient was entered in the analysis to
void confounding secondary to within-patient depen-
ence. This occurred in 74 patients (3% of the total). Last,
e eliminated any patient who was enrolled in the Proj-
ct or Ex-Vivo vein graft Engineering via Transfection
II (PREVENT III) trial or any other cohort represented
n the SVS OPG dataset. This occurred in 24 patients across
wo centers (1% of the total), and these patients were,
herefore, eliminated from the analyses. Therefore, our
ohort consisted of 1039 patients who underwent 1039
EB procedures. Follow-up times varied from 1 month to
5 months, with a median of 12.8 months (SD of 5.2
onths).
Definitions and outcome measures. Our unit of
nalysis was the patient, given that only one procedure
er patient was analyzed. Patients were evaluated for pre-
xisting medical comorbidities, and these data were pro-
pectively entered into our registry by specifically trained
urgeons, nurses, or clinical data abstractors. Over 70 clin-
cal and demographic variables were collected on each
atient.22,23 Validation analyses to ensure complete sub-
ission of data were performed using hospital discharge
bstracts. Furthermore, we used the Social Security Death
ndex to ensure that all deaths had been recorded in our
ataset. Demographic data and the incidence of patient-
evel comorbidities are outlined in Table II.
Our main outcome measures were the OPGs them-
elves, recorded at 30 days for the safety OPGs, and 1 year
or the efficacy OPGs (Table I). In univariate analyses, we
ompared the OPGs from the SVS data to those results
erived from procedures performed within the VSGNE,
sing 2 for categorical variables (the safety measures stud-ed at 30 days). We examined the efficacy outcomes at 1
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low-risk strata within VSGNE analytical groups over a
1-year period, and compared survival data and its surround-
ing 95% confidence intervals (CIs) between OPG data and
VSGNE datasets.
Risk adjustment: high-risk subgroups and population-
specific objective performance goals. The SVS OPG inves-
tigators used regression models to identify key variables
that were associated with poor outcomes at 1 year. They
designated patients with several important characteristics to
be “high-risk.” These high-risk groups were designated as
clinical high-risk (age over 80 and tissue loss), anatomic
high-risk (infrapopliteal distal target), and conduit high-
risk (absence of single-segment great saphenous vein
Table II. Patient characteristics in the Vascular Study Gro
Variable
VSG
(n
Nu
cha
Female gender
African American
Age over 65
Age over 80
Hypertension
Diabetes (all diabetics)
Statin
Previous ipsilateral leg surgical interventions
Previous ipsilateral leg surgical/endovascular intervention
Ulcer/gangrene (not rest pain)
Clinical high risk
Anatomic high risk
Conduit high risk
CLI, Critical limb ischemia; OPG, objective performance goal; SVS, Society
aCalculated out of 690 patients; statin use unavailable in remainder.
bCalculated out of 605 patients; conduit size unavailable in remainder.
Table III. Safety and efficacy objective performance goals
performance goal cohort and the Vascular Study Group of
SVS OPG cohort
(mean, 95% CI) (
Safety outcomes at 30 days
MALE (amputation or major
reintervention)
6.1% (4.6-7.9) 3
MACE (MI, stroke or death) 6.2% (4.7-8.1) 4
Above-ankle amputation 1.9% (1.1-3.1) 1
Efficacy outcomes at 1 year
Freedom from MALE or
POD
76.9% (74.0-79.9) 74
Limb salvage 88.9% (86.7-91.1) 90
Survival 85.7% (83.3-88.1) 91
AFS 76.5% (73.7-79.5) 84
Freedom from RAS 46.5% (42.3-51.2) 67
Freedom from RAO 61.3% (58.0-64.9) 72
AFS, Amputation-free survival; CI, confidence interval; MACE, major adve
goal; POD, postoperative death; RAO, reintervention or amputation; RAS,
VSGNE, Vascular Study Group of New England.greater than 3 mm in diameter). For these efficacy outcome Oeasures, comparisons between high-risk and low-risk
trata were made using log-rank tests at 1-year follow-up.
Further, we were then able to use these high-risk
riterion and their associated beta coefficients from uni-
ariate regression models to calculate population-specific
PGs for the VSGNE cohort, based on each individual
atient’s high-risk criteria. An example of how the VSGNE
opulation-specific OPG for major adverse limb events
MALE)  postoperative death (POD) OPG outcome is
alculated is illustrated below.
ALE or death within 30 days
PG  (73.8586%-0.0622* [% infrapopliteal distal tar-
get])
f New England and objective performance goal cohorts
cohort
39)
SVS OPG cohort
(n  838)
Proportion P value
with
ristic Proportion
Number with
characteristic
32.2% 282 33.7% .31
0.7% 116 13.8% .001
65.5% 570 68.0% .42
20.4% 161 19.2% .59
86.3% 640 76.4% .02
57.5% 477 56.9% .74
54.3% 339 49.1% .016a
14.3% 100 11.9% .1
29.0% 136 16.2% .001
65.5% 618 73.7% .02
15.3% 136 16.2% .58
57.8% 505 60.3% .32
10.2% 163 26.9% .001b
ascular Surgery; VSGNE, Vascular Study Group of New England.
ults from the Society for Vascular Surgery objective
England
GNE
, 95% CI)
P value
(SVS-OPG vs VSGNE)
OPG for endovascular
procedures
2.3-4.6) .05 8%
3.3-5.4) .35 8%
1.2-2.9) .71 3%
70.9-77.0) .58 71%
86.1-92.8) .33 84%
88.0-93.5) .10 80%
79.0-86.2) .15 71%
64.0-70.4) .02 39%
69.1-75.3) .03 55%
diac event; MALE, major adverse limb event; OPG, objective performance
rvention, amputation, or graft stenosis; SVS, Society for Vascular Surgery;up o
NE
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OPG  (72.8532%-0.1575* [% clinical risk])
The coefficients used in the four remaining efficacy
outcomes are shown in Appendix B (online only). Finally,
to account for all of the patient-level covariates in the
calculation of each individual OPG, all the covariates were
entered into multivariate models derived to predict each
efficacy OPG based on each patient’s individual character-
istics. The multivariate equations for each OPG are shown
in Appendix B (online only). These multivariable models
take into consideration the patient-specific variables of an-
atomic, clinical, and conduit risk in determining each pa-
tient’s individual risk of meeting each of the OPGs. By
aggregating patients across the cohort, we were then able
to generate population-specific OPGs for the patients that
comprised the VSGNE cohort. All analyses were performed
using Microsoft Excel (Redmond, Wash) and Stata (Col-
lege Station, Tex). The Institutional Review Board at Dart-
mouth Medical School reviewed and approved our study
protocol.
RESULTS
Patient characteristics. The 1039 patients who un-
derwent 1039 LEB procedures in the VSGNE cohort were
most commonly men (66%), elderly (mean age of 73 years),
and white (99%; Appendix C, online only; Table II). Nearly
all patients had a history of either prior or current smoking
(79%). Over half of the patients (58%) had a history of
diabetes, 40% had coronary disease, and nearly one-third
Table IV. Calculation of VSGNE-specific OPGS
Patient
characteristic
Po
Proportion
in VSGNE
MALE 
POD OPG
MALE  POD
result for this
subgroup in VSG
(mean, 95% CI)
P val
SVS
V
Infrapopliteal
target
57.8% 73.8% 69.3% (65.1-74.0)
Age 80 20.4% 72.9% 74.1% (66.8-80.3)
Tissue loss 65.5% 70.8% 71.4% (67.5-75.0)
High clinical
risk
15.3% 72.8% 70.8% (62.3-77.8)
Populatio
Patient
characteristic
Limb
salvage
OGP
Limb salvage result
for this subgroup
in VSG
(mean, 95% CI)
P valu
SVS O
VS
Infrapopliteal
target
86.3% 88.0% (84.5-90.8)
Age 80 84.1% 90.5% (84.5-94.3)
Tissue loss 90.2% 90.0% (87.0-92.4)
High clinical
risk
84.4% 88.6% (81.0-90.4)
CI, Confidence interval; MALE, major adverse limb event; NS, not significa
Vascular Surgery; VSG, Vascular Study Group; VSGNE, Vascular Study Gro(30%) had a history of chronic obstructive pulmonary qisease. The majority of patients with CLI presented
ith tissue loss (65%), as opposed to rest pain (35%).
urther, while all patients had available autogenous con-
uit, 13% used alternative types of autogenous conduit
uch as composite vein (7%), arm vein (4%), or lesser
aphenous vein (2%). Further details about the charac-
eristics of the cohort used are available in Appendix C,
nline only, Table II.
Overall, while patients in the VSGNE cohort were
imilar to patients in the SVS OPG cohort, small but
ignificant differences exist between the two groups (Table
I). For example, patients in the VSGNE cohort were less
ikely to be African American (0.7% VSGNE; 13.8% SVS
PG; P  .001) and more likely to have hypertension
86.3% VSGNE; 76.4% SVS OPG; P  .02). VSGNE
atients were also more likely to be on statins (54.3%
SGNE; 49.1% SVS OPG; P  .016) and to have under-
one previous vascular interventions (29.0% VSGNE;
6.2% SVS OPG; P  .001), but fewer had tissue loss
65.5% VSGNE; 73.7% SVS OPG; P  .02) Overall, the
roportion who were designated as clinically high-risk was
lightly lower (15.3 VSGNE; 16.2% SVS OPG; P .58), as
as the proportion designated as anatomically high risk
57.8% VSGNE; 60.2% SVS OPG; P .48). However, the
roportion designated as conduit high-risk differed be-
ween datasets (10.20% VSGNE; 26.9% SVS OPG; P 
001). Some of this difference may be attributable to
ifferences in definition of an acceptable saphenous vein.
t is important to note that while the SVS cohort re-
ion-specific OPG
ween
and
E
Amputation-free
survival OPG
Amputation-free
survival result for this
subgroup in VSG
(mean, 95% CI)
P value between
SVS OPG and
VSGNE
72.3% 81.3% (77.4-84.7) .04
74.0% 76.4% (69.2-82.1) NS
78.8% 81.8% (78.3-84.9) NS
73.8% 72.5% (63.9-79.3) NS
ific OPG
een
nd Death
OPG
Death result for
this subgroup
in VSG
(mean, 95% CI)
P value between
SVS OPG and
VSGNE
78.6% 91.7% (88.8-93.3) .03
83.9% 83.7% (77.1-83.5) NS
82.7% 90.2% (87.4-92.5) .03
83.6% 81.0% (72.9-86.8) NS
G, objective performance goal; POD, postoperative death; SVS, Society for
New England.pulat
ue bet
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SGN
NS
NS
NS
NS
n-spec
e betw
PG a
GNE
NS
.05
NS
NS
nt; OPuired the vein to be 3 mm in diameter, the VSGNE
s
g
V
a
j
f
V
e
a
c
i
m
T
O
O
8
s
S
V
V
O
w
l
(
w
o
(
w
e
l
e
t
a
D
c
t
n
a
i
i
e
O
t
t
d
r
s
r
l
s
a
r
JOURNAL OF VASCULAR SURGERY
July 2011104 Goodney et alcohort did not have size parameters on their definition;
rather, the vein was simply categorized as “acceptable.”
The more stringent definition used in the SVS OPG
cohort may have, therefore, contributed to the higher
proportion of patients designated as “conduit high-risk”
in the SVS OPG cohort.
Safety outcomes and suggested objective perfor-
mance goals in the VSGNE. The three safety OPGs
studied at 30 days after surgery were MALE (amputation or
major reintervention), major adverse cardiovascular events
(MACE; myocardial infarction, stroke, or death), and ma-
jor above-ankle amputation. The main safety OPG, MALE
at 30 days, occurred in 6.1% (95% CI, 4.6%-7.9%) of
patients in the SVS derivation dataset. In our cohort, we
found that the MALE rate was slightly lower (3.2%, 95%
CI, 2.3%-4.6%; P  .05). The second safety OPG, major
amputation rate before 30 days, was similar in both the SVS
and VSGNE datasets (SVS  1.9%; 95% CI, 1.1-3.1),
VSGNE  1.9 (95% CI, 1.2-2.9; P  .71). Finally, the
third safety OPG, major adverse cardiac event rate, was also
similar between the two groups, as shown in Table III
(SVS  6.2%; 95% CI, 4.7-8.1), VSGNE  4.2 (95% CI,
3.3-5.4; P  .35).
Efficacy measures and suggested objective perfor-
mance goals in the VSGNE. We compared the efficacy
outcomes established by the SVS OPGs with those calcu-
lated in the VSGNE. We found that the VSGNE dataset
met all the efficacy OPGs suggested by the SVS (Table III).
For example, for the main efficacy OPG, freedom from
MALE, or POD, results were very similar between the SVS
OPG dataset and the VSGNE (77%; 95% CI, 74%-80%)
SVS OPG, 74% (95% CI, 71%-77%) VSGNE, P  .58).
This trend was similar for the remaining OPGs, including
limb salvage, survival, and amputation-free survival rates
(Table III). Freedom from reintervention or amputation
within the first year continued to reflect the slightly lower
rate of reinterventions in the VSGNE dataset within the
first year.
Risk adjustment: high-risk subgroups and multi-
variable modeling to predict risk. Next, we studied out-
comes within the three high-risk subgroups (anatomic,
clinical, and conduit) defined by the SVS OPG working
group (Table IV). Overall, we found that in the VSGNE,
15% of patients were defined as clinical high-risk, 58% of
patients were anatomic high-risk, and 10% used bypass
conduit designated as high-risk.
First, we studied if the variables that were important in
delineating high-risk and low-risk populations in the SVS
OPG cohort accomplished the same task in the VSGNE
cohort. We found that these risk subgroups discriminated
performance well (Fig 1). For example, across all three
subgroups, using the MALE  POD efficacy OPG, pa-
tients in the lower risk category had significantly better
outcomes at 1 year (log-rank P  .01). Findings were
similar across the entire remaining efficacy OPGs (Appen-
dix D, online only).
Second, we questioned if outcomes were similar across
high-risk subpopulations. For example, the population- cpecific OPG for MALE  POD in the anatomic high-risk
roup is 74.0%. While the MALE  POD result in the
SGNE cohort was slightly lower at 69.3%, the 95% CIs
round the VSGNE dataset (65.1-74.0) included the ad-
usted OPG. Therefore, the VSGNE dataset met the OPG
or this measure. Across all of the high-risk subgroups, the
SGNE cohort met or exceeded the OPG, indicating that
ven in high-risk patient subgroups, OPGs represent an
ttainable benchmark in real-world practice.
But what if a patient is high-risk across more than one
ategory? This same calculation can be undertaken, adjust-
ng for all of the risk categories simultaneously, using the
ultivariate models described in Appendix B (online only).
hese multivariate models calculate population-specific
PGs, based on each of the four inputs used in the SVS
PG multivariate model (infrapopliteal anatomy, age over
0, tissue loss, and conduit). We found these population-
pecific “adjusted” OPGs were, on average, similar to the
VS OPGs—reflecting the relative similarities in the
SGNE and SVS patient populations.
As shown in Fig 2, the outcomes achieved in the
SGNE cohort generally met or exceeded the adjusted
PG for all of the efficacy endpoints. Any instances
herein differences occurred between the VSGNE (Vascu-
ar Study Group [VSG]) outcomes and OPGs benchmarks
such as survival) were small and not clinically significant,
ith two notable exceptions: reintervention, amputation,
r graft stenosis (RAS) and reintervention or amputation
RAO). These differences in the RAS and RAO endpoints,
here the VSGNE cohort had significantly fewer adverse
vents of reintervention, amputation, or graft stenosis,
ikely represent an underestimate of the occurrence of these
ndpoints in the VSGNE dataset, because not all patients in
he VSGNE dataset underwent routine surveillance duplex
t 1-year follow-up.
ISCUSSION
Patients and their physicians are faced with difficult
hoices when making treatment decisions for CLI. While
raditional surgical bypass is established and effective, alter-
ative endovascular therapies have emerged as a popular
lternative, most likely because they avoid invasive therapies
n this frail patient population.11 However, trials compar-
ng these two modalities have proven difficult to design and
xpensive to perform. Therefore, the SVS has designed
PGs as a mechanism to provide benchmarks by which
he performance of endovascular interventions and other
reatment modalities can be measured. As our study
emonstrates, even though these benchmarks were de-
ived using data from highly selected clinical trials, they
eem to accurately reflect the outcomes achieved in
eal-world LEB.
The generalizability of SVS OPGs, across highly se-
ected clinical trials as well as within everyday vascular
urgery practice, suggests that these benchmarks are an
ccurate performance measurement tool in lower extremity
evascularization for patients with CLI. Further, the strong
orrelation between the outcomes of clinical trials and
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tients have widely available access to high-quality surgical
lower extremity revascularization for CLI. Unlike early
clinical trials of asymptomatic carotid endarterectomy,24
wherein clinical trial results did not always translate into
real-world outcomes, it seems that patients can be assured
of similar outcomes regardless of the setting in which they
undergo surgery.
This report adds to the growing evidence from clin-
ical trials,12,18-21 academic centers,25,26 and regional
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Fig 1. Major adverse limb events (MALE) and postop
subgroups.collaboratives8 that demonstrate that LEB is effective, deproducible, and broadly available. Therefore, policy-
akers and payers should ensure that endovascular in-
erventions meet a similar benchmark. Many will argue
hat patients may accept shorter patency or higher rein-
ervention rates for endovascular interventions, based on
heir less-invasive approach. This process occurred in the
reatment of coronary artery disease.27-30 While it is well
nown that patients will often “discount” a desired
utcome based on a less morbid approach and shorter
ecovery,31,32 the extent of this trade-off has yet to be
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July 2011106 Goodney et alopen surgery, it is likely that patients and providers will
“vote with their feet” and choose the surgical procedure
or endovascular intervention that they believe will pro-
vide the most effective treatment. However, the first step
in determining treatment efficacy and effectiveness is to
define the outcome measures, and our analysis demon-
strates that the SVS OPGs represent plausible, achievable
targets for patients with CLI.
Many will question why the SVS OPGs, which were
primarily derived to determine endpoints for clinical trials,
should matter to surgeons interested in quality improve-
ment, such as those surgeons in the VSGNE. However, the
essential components of any quality improvement effort, as
outlined by Deming, usually involve a Plan/Do/Study/
Act cycle.33 In a Plan/Do/Study/Act cycle, a process is
improved by planning how change will be implemented,
implementing the change, studying the effect of change,
and acting upon the results of these studies. We believe the
SVS OPGs offer the advantage of standardization of out-
comes during the “study” phase of these efforts. Many have
documented wide variation in the assessment of efficacy in
Fig 2. Proportion of patients remaining free from m
Vascular Study Group of New England (VSGNE), with
within the VSGNE after adjustment for the proportion of
(SVS adj for VSG). AFS, Amputation-free survival; MALE
reintervention or amputation; RAS, reintervention, ampthe study of lower extremity revascularization.1,2,8,10 This eroblem limits effectiveness and generalizability, not only
n clinical trials, but quality improvement efforts as well. By
tandardizing outcome assessment, OPGs can help to fur-
her efforts in the study of lower extremity revasculariza-
ion, across both clinical trials of new devices as well as in
tructured quality improvement efforts.
Our study has several limitations. First, there are small
ifferences between the definitions in the SVS OPG dataset
nd our VSGNE dataset. For example, reinterventions are
ategorized as catheter-based, surgical, or both in the
SGNE. However, a major/minor categorization scheme
s used in the SVS OPG definition. Despite these disparities,
he absolute differences in most of the efficacy endpoints
etween the two datasets were small (less than 5% at 1 year).
econd, data within the VSGNE are self-reported by its
articipating centers and are not independently adjudi-
ated, nor was duplex evaluation at 1 year mandated in our
ataset. However, for two reasons, we believe our results
ccurately reflect outcomes with LEB in our region. First,
articipation in our regional quality improvement database
s voluntary, and surgeons who freely allocate their time and
each objective performance goal (OPG) within the
e Society for Vascular Surgery (SVS) OPG cohort, and
nts with clinical, anatomic, and conduit high-risk criteria
jor adverse limb event; POD, postoperative death; RAO,
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follow-up visits are coded by nursing or research personnel,
limiting (to some extent) reporting bias, as compared to
self-reporting by the operating surgeon. Third, our dataset
is validated for inclusion and outcomes by comparing
VSGNE outcomes with hospital billing data and the Social
Security Death Index, as outlined in several prior re-
ports.8,23,34,35 Our third limitation centers around our
measurement and definition of CLI in our cohort. In the
SVS OPG cohort, hemodynamic criteria were used to
support the diagnosis of CLI in the randomized trials.
Extensive information was collected as line-item data to
determine each patient’s ankle pressure, toe pressure, or
TcPO2, with specific criteria required for inclusion (ankle
pressure 50, toe pressure 30, TcPO2 30). In the
VSGNE, hemodynamic criterion was available to confirm
the diagnosis of CLI both before and after surgery in 47% of
our patients with CLI. Within this group, the mean toe
pressure was 0.2, and the mean ankle pressure was 0.38,
lending credence to the diagnosis of CLI, at least in these
patients. However, a sizeable portion of patients in our
cohort do not have these variables routinely recorded, as
our registry does not mandate practice patterns, and some
surgeons in our dataset do not routinely measure ankle-
brachial indexes at follow-up, especially in clinical settings
where the significance is uncertain (such as a palpable graft
pulse). However, realizing the value of these data in com-
parative research, more complete evaluation of hemody-
namic data in patients with CLI remains an ongoing focus
of our data collection improvement process. Fourth,
while VSGNE outcome satisfied the SVS OPGs in our
analyses, in some instances, this occurred only by using
the 95% CI around the point estimate of the VSGNE
outcome. For example, the SVS OPG freedom from
MALE/POD outcome at 1 year was 77%, while this
value in the VSGNE was only 74%, with a 95% CI that
included 77%. Whether or not the SVS OPGs should be
considered as a “hard target” and be considered unsatis-
fied if the actual point estimate is not reached, remains a
question for future discussion. Fifth, given the observa-
tional nature of the VSGNE dataset, unmeasured con-
founders may have impacted our outcomes. However,
the similarities between the results from the VSGNE
dataset and the randomized trials from which the SVS
OPGs were derived argue against any significant effect of
any unmeasured confounders.
In summary, the development and broad implementa-
tion of the SVS OPGs in clinical trials, quality improvement
efforts, and overall clinical assessment of lower extremity
revascularization represents an achievable opportunity to
advance the science of how vascular surgeons measure
success or failure. However, looking forward, the current
SVS OPGs represent the beginning of this effort, and
expansion toward even more in-depth OPGs lies ahead. For
example, the current SVS OPGs do not take into account
quality of life, nor do they reflect the use of medical
adjuncts such as antiplatelet agent or statin use. Given the
focus of payers, providers, and policymakers on functionalutcomes as well as evidence-based medicine, our future
fforts will hope to shape new OPGs that will address the
bility of vascular surgeons to design and achieve bench-
arks in these critical areas.
ONCLUSIONS
The OPGs suggested by the SVS accurately represent
roadly achievable targets in LEB surgery, irrespective of
hether the procedure is performed within a clinical trial,
n academic center, or in a community setting. Further-
ore, in our region, LEB surgery performed in the context
f a regional quality improvement registry demonstrates
utcomes that are consistent with those found in multi-
enter randomized trials. Vascular surgeons interested in
easuring the quality of treatment of patients with lower
xtremity PAD should use the SVS OPGs to study, report,
nd improve their outcomes.
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Hospitals participating in the Vascular Study Group of
New England
Catholic Medical Center, Manchester, NH
Central Maine Medical Center, Lewiston, Me
Concord Hospital, Concord, NH
Cottage Hospital, Woodsville, NH
Dartmouth–Hitchcock Medical Center, Lebanon, NH
Eastern Maine Medical Center, Bangor, Me
Fletcher Allen Health Care, Burlington, Vt
Lakes Regional General Hospital, Laconia, NH
Maine Medical Center, Portland, Me
Mercy Hospital, Portland, Me
UMass Memorial Medical Center, Worcester, Mass
Appendix B (online only)
Univariate calculation of OPGs
MALEPOD:
OPG  73.8%0.0622* (% infrapopliteal)
OPG  72.9%0.1386* (% age   80)
OPG  70.8%0.0089* (% tissue loss)
OPG  72.8%0.1575* (% clinical risk)
AFS:
OPG  72.3%0.0436* (% infrapopliteal)
OPG  74.0%0.2166* (% age   80)
OPG  78.8%0.1238* (% tissue loss)
OPG  73.8%0.2463* (% clinical risk)
Amputation:
OPG  86.3%0.053* (% infrapopliteal)
OPG  84.1%0.045* (% age   80)
OPG  90.3%0.096* (% tissue loss)
OPG  84.4%0.072* (% clinical risk)
Death:
OPG  78.6%0.014* (% infrapopliteal)
OPG  83.9%0.225* (% age   80)
OPG  82.7%0.042* (% tissue loss)
OPG  83.6%0.243* (% clinical risk)
RAS:
OPG  78.6%0.014* (% infrapopliteal)
OPG  83.9%0.225* (% age   80)
OPG  82.7%0.042* (% tissue loss)
OPG  83.6%0.243* (% clinical risk)
RAO:
OPG  78.6%0.014* (% infrapopliteal)
OPG  83.9%0.225* (% age   80)
OPG  82.7%0.042* (% tissue loss)
OPG  83.6%0.243* (% clinical risk)
Multivariate Calculation of OPGs
AFS OPG  0.765870268 0.001106445 (conduit high
risk) 0.000223133 (popliteal outflow) 0.003513622
(clinical high risk)
MALE  POD OPG  0.794055728 0.001754896
(conduit high risk)0.000703511 (popliteal outflow)
0.002245621 (clinical high risk)EATH OPG0.8203557450.00094661 (conduit high
risk) 0.000843207 (popliteal outflow) 0.00349814
(clinical high risk)
MPUTATION OPG  0.893816479 0.000848383
(conduit high risk)0.000419496 (popliteal outflow)
0.001336974 (clinical high risk)
AS OPG  0.48667683 0.003452089 (conduit high risk)
0.0000097161 (popliteal outflow)0.002209077 (clin-
ical high risk)
AO OPG  0.631924841 0.003016539 (conduit high
risk)0.000301062 (popliteal outflow)0.001228289
(clinical high risk)
AFS, Amputation-free survival; OPG, objective perfor-
ance goal; POD, postoperative death; RAO, reinterven-
ion or amputation; RAS, reintervention, amputation, or
raft stenosis.
ppendix C (online only). Patient characteristics in
he VSGNE cohort
ariable
VSGNE cohort
(n  1039)
ale gender 68%
ight side 51%
on-white race 2%
ot living home preoperatively 5%
ot independently ambulatory preoperatively 29%
ge
40 1%
40-50 5%
50-60 16%
60-70 26%
70-80 32%
80-90 18%
90-100 2%
moking (prior or current) 80%
COPD 29%
iabetes (all diabetics) 58%
Non-insulin-dependent diabetics 21%
Insulin-dependent diabetics 37%
oronary disease 36%
ongestive heart failure 21%
est pain 32%
issue loss 68%
oncomitant ipsilateral proximal angioplasty/stent 4%
reoperative medication regimen
Antiplatelet agent use 70%
Preoperative statin use 54%
Preoperative beta blocker use
No beta blocker 16%
Perioperative beta blocker 24%
Chronic beta blocker 60%
perative characteristics
External iliac origin 1%
Common femoral origin 61%
Profunda origin 4%
Superficial femoral artery origin 22%
Above-knee popliteal origin 5%
Below-knee popliteal origin 8%
Superficial femoral artery recipient 1%
Above-knee popliteal recipient 10%
Below-knee popliteal recipient 31%
Tibio-peroneal trunk recipient 3%
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Variable
VSGNE cohort
(n  1039)
Anterior tibial recipient 14%
Posterior tibial recipient 15%
Peroneal recipient 10%
Posterior tibial artery at ankle recipient 6%
Dorsalis pedis recipient 8%
Tarsal recipient 2%
Anesthesia type
General anesthesia 72%
Epidural 10%
Spinal 18%
Conduit
In situ great saphenous vein 45%
Reversed great saphenous vein 28%
Nonreversed transposed great saphenous vein 15%
Lesser saphenous vein 1%
Cephalic/basilic vein 4%
Composite vein 7%
Completion study (duplex or arteriogram) 73%
VSGNE, Vascular Study Group of New England; COPD, chronic obstruc-
tive pulmonary disease.
Appendix D (online only).
Death OPG: (all curves have SE 0.10.)
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